Histone deacetylase inhibitors in cancer therapy Is transcription the primary target? by Johnstone, Ricky W & Licht, Jonathan D
CANCER CELL : JULY 2003 · VOL. 4 · COPYRIGHT © 2003 CELL PRESS 13
Introduction
Characterization of transcriptional repressor fusion proteins in
acute leukemia and growing evidence of the importance of epi-
genetic changes in cancer onset and progression have stimulat-
ed interest in the manipulation of transcription as a mode of
cancer therapy. Altering gene expression through chromatin
modification now seems to be a viable clinical target. Consistent
with this, histone deacetylase inhibitors (HDI) are now being
tested for the treatment of leukemia and solid tumors. While
these agents show promise, their mechanism(s) of action and
selective toxicity against tumor cells have not yet been ade-
quately defined. While the altered expression of specific genes
by HDI is important for certain biological outcomes, their effects
on other histone-regulated cellular processes, such as mitosis,
may be equally important for the antitumor activity.
Aberrant transcriptional repression is common in cancer
Studies from the 1970s indicated that active chromatin was
hyperacetylated while inactive, silenced genes were deacetylated
and often cytosine methylated.Transcriptional activators can bind
and recruit histone acetyl transferases (HAT) while transcriptional
repressors and co-repressors interact with histone deacetylases
(HDAC) (Melnick and Licht, 2002). In general, binding of repres-
sors and HDACs at promoters correlate with loss of histone
acetylation while activator proteins are associated with acetylated
chromatin. Furthermore, a more complex code of histone tail
modifications including acetylation, methylation, phosphorylation,
and ubiquitylation, all potentially amenable to pharmacological
modification, has been described to help explain the epigenetic
regulation of gene expression (Jenuwein and Allis, 2001). In addi-
tion to targeting histone tails, HATs and HDACs can modify other
proteins including transcription factors, resulting in altered DNA
binding and transcriptional activity.
Aberrant regulation of gene expression is a hallmark of
many forms of cancer. In leukemia, chimeric fusion proteins pro-
duced by chromosomal translocations alter normal gene
regulation through modification of chromatin. The PML-
RARα,protein of acute promyelocytic leukemia (APL) and
AML1-ETO generated by t(8;21) aberrantly recruits histone
deacetylases to target genes leading to repression of otherwise
active genes. This results in a differentiation block, contributing
to tumor development. Aberrant transcriptional repression may
occur following overexpression of nonmutated repressor pro-
teins as in the case of Bcl6 in lymphoma. Altered repression in
cancer may also result from overexpression of histone modify-
ing proteins. Histone methylation at particular sites by SET
domain proteins is associated with gene silencing (Jenuwein
and Allis, 2001). The EZH2 SET protein overexpressed in
metastatic prostate cancer might inhibit gene expression in
such a manner.
Specific regions of the genome of the cancer cell are fre-
quently aberrantly hypermethylated leading to silencing of
tumor suppressor genes such as INK4A (Jones and Baylin,
2002). Methylated cytosine residues bind factors like MECP2
that can further recruit DNA methyltransferase and HDAC-con-
taining complexes to propagate and/or maintain gene silencing.
How genes become selectively hypermethylated is for the most
part unknown; however, the process may be initiated by onco-
genic transcription factors such as PML-RARα, which can
recruit DNA methyl transferases, leading to silencing of RARα
targets (Di Croce et al., 2002). DNA methylation is a dominant
silencing process and in general methylated genes cannot be
reactivated by histone hyperacetylation alone. Reexpression of
methylated genes may in some cases be achieved by treatment
with 5-Azacytidine (5Aza), which sequesters DNA methyltrans-
ferases. However, the combination of 5Aza and an HDI can syn-
ergistically reactivate silenced genes (Jones and Baylin, 2002).
The reversal of aberrant gene repression could thus benefit
a wide range of malignancies. Furthermore any component of
the repression complex; DNA, transcription factor, co-factor, or
modifying enzyme might be a therapeutic target. While protein-
protein and protein-DNA interactions are considered very diffi-
cult to inhibit pharmacologically, enzymes like the HDACs are
considerably more tractable. Accordingly, a number of HDI are
now in preclinical development and early clinical trial.
Histone deacetylases and their inhibitors
HDACs are divided into three classes. Class I HDACs are gen-
erally nuclear and associate with transcriptional repressors and
co-factors. Class II HDACs are larger proteins and can shuttle
between the cytoplasm and nucleus. HDAC6 contains two cat-
alytic domains, one of which is specific for tubulin and not for
histones (Hubbert et al., 2002). This highlights the important
point that HDACs are protein deacetylases and many of the
effects of these proteins and their inhibitors could be mediated
by modification of nonhistone proteins. Class I and II HDACs are
similar to a bacterial histone deacetylase-like protein (HDLP)
with a catalytic pocket at the base containing a critical zinc ion
and a hydrophobic pocket allowing for the insertion of a lysine
side chain. Class III HDACs or sirtuins require nicotinamine
adenine dinucleotide as a 1:1 co-factor with substrate. These
enzymes may sense the metabolic state and age of the cell
(Grozinger and Schreiber, 2002). Mammalian SirT1 deacety-
lates p53 altering its function as a tumor suppressor (Langley et
al., 2002) while SirT2 is a microtubule deacetylase (North et al.,
2003).
Both naturally occurring and synthetic HDI have been char-
acterized (Johnstone, 2002; Kelly et al., 2002). HDI are struc-
turally diverse, ranging from simple compounds (i.e., butyrate)
to more complex agents such as hydroxamic acids (i.e.,
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suberoylanilide hydroxamic acid [SAHA]), cyclic teratpeptides
(i.e., depsipeptide), and benzamides (i.e MS-275). Hydroxamic
acids are potent HDI and contain a functional group that inter-
acts with the critical HDAC zinc atom, a 5-6 carbon aliphatic
chain which mimics a lysine side chain, and a hydrophobic cap
moiety which interacts with the edge of the catalytic pocket and
could play a role in HDAC selectivity (Grozinger and Schreiber,
2002). In contrast, HDI with lower potency such as phenylbu-
tyrate and valproic acid (VPA) possess an acyl group to contact
the catalytic zinc ion but cannot make significant contact with
the catalytic pocket due to their very short side chains. In gener-
al, HDI show broad activity with most HDIs able to inhibit the
activity of the more than ten Class I/II HDACs. Exceptions
include the hybrid cyclic tetrapeptide/hydroxamic acid peptides
(CHAP) which have a preference for HDAC1 and 4 over HDAC6,
and the recently identified tubacin which specifically targets the
tubulin-specific catalytic domain of HDAC6 and does not affect
histone acetylation (Haggarty et al., 2003). A specific HDI might
be desired if a particular HDAC forms part of an oncogenic
repressive complex. However, given the large number of HDACs
present in most cells and the prospect of functional redundancy,
it is not clear if isoform-specific HDI will be advantageous for
most clinical purposes.
HDIs can have a range of antitumor activities including
induction of cell cycle arrest, stimulation of differentiation, and
provocation of apoptosis. The simplest, almost dogmatic expla-
nation of these effects is that HDIs primarily target transcription
to induce their biological effects. This idea has not yet been rig-
orously proved.
HDIs induce differentiation in acute leukemia
In situations where altered gene expression is clearly linked to
disease onset and progression, relief of transcriptional repres-
sion may have a beneficial clinical effect. HDIs relieve repres-
sion of reporter genes mediated by chimeric oncoproteins such
as PML-RARα, PLZF-RARα, and AML-ETO and induce differ-
entiation and terminal division of cells harboring these translo-
cations when combined with all-trans retinoic acid (ATRA) or
granulocyte colony stimulating factor (G-CSF). APL associated
with PLZF-RAR is insensitive to ATRA therapy due to the consti-
tutive ability of PLZF to recruit HDACs. However, treatment of
these leukemic cells with ATRA + trichostatin A (TSA) or SAHA
results in cell differentiation and significant apoptosis (He et al.,
2001) (Figure 1A).
Can modulation of transcription to force the differentiation of
the tumor be extended to other forms of leukemia and cancer?
Pediatric tumor cells harboring the EWS-FLI fusion protein
exhibit decreased expression of TGFβ-receptor II; this can be
reversed by treatment with MS-275 consistent with a chro-
matin/transcriptional effect (Jaboin et al., 2002). Moreover,
leukemic blasts from patients without the characteristic APL
chromosomal translocation differentiated with a combination of
ATRA and TSA or VPA (Ferrara et al., 2001; Gottlicher et al.,
2001). ATRA alone did not induce differentiation, but the combi-
nation stimulated known RARα target genes. Unfortunately, the
chromatin state of these targets was not examined, and hence
formal proof that the HDIs affected chromatin to stimulate differ-
entiation is lacking. Nevertheless, it appears that HDIs release a
block to RARα function in many forms of AML. This could be
due to modulation of chromatin at retinoic acid receptor (RAR)
target loci or even due to modifications of the RAR itself. The
notion that HDIs may extend the therapeutic effects of ATRA
into other forms of leukemia led our group to initiate clinical tri-
als of VPA in leukemia.
HDI monotherapy induces cell cycle arrest, cell
maturation, and changes in gene expression
Treatment of tumor cell lines with HDIs often induces G1 cell
cycle arrest and differentiation (Figure 1B). These effects are
correlated with the transcriptional activation of CDKN1A,
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Figure 1. Transcriptional models of the anticancer actions of HDIs
A: HDIs Reverse the repressive effects of fusion transcription factors on target genes.
B: HDIs induce p21WAF1/CIP1 to cause G1 arrest and differentiation. Proapoptotic genes may be induced as well.
C: HDIs in combination with 5-Aza reactivate silenced tumor suppressor genes.
CANCER CELL : JULY 2003 15
encoding the CDK inhibitor p21WAF1/CIP1 in a p53-independent
manner (Richon et al., 2000). Induction of p21WAF1/CIP1appears to
be important for HDI-induced differentiation as it can initiate
myeloid differentiation and cells devoid of p21WAF1/CIP1 are resis-
tant to the differentiation effects of HDIs (Archer et al., 1998).
Cell cycle arrest by HDIs may also be mediated by altered
expression of cyclins A and D and p27KIP1, resulting in
decreased activity of cdk4 and cdk2 (Johnstone, 2002). Other
potential growth inhibitory mechanisms include induction of
other cell cycle regulatory genes such as GADD45α and β
(Chen et al., 2002) and upregulation of the TGFβ receptor sig-
naling, leading to repression of c-myc and cell cycle arrest
(Jaboin et al., 2002). In these situations, the growth arrest medi-
ated by HDI is proposed to occur through the direct effects of
HDI on chromatin architecture at specific loci leading to
changes in gene expression.
Gene profiling studies indicate that HDI modulate only
4%–12% of genes and surprisingly, a similar proportion of
genes are activated and repressed, although often with different
kinetics. Many of the same genes are regulated by structurally
diverse HDIs, suggesting that certain loci are in a highly plastic
state and that the HDIs can converge on common targets. In
colon cancer cells, TSA and butyrate regulated a similar set of
genes with different kinetics, correlating with the more rapid
induction of histone acetylation by TSA (Mariadason et al.,
2000). SAHA and TSA induced a similar set of genes in breast
cancer cells while MS-275, which had no effect on tubulin acety-
lation, regulated a different set of genes, underscoring the pos-
sible importance of nonhistone targets of HDIs (Glaser et al.,
2003). The reason for the relatively low and select number of
genes affected by a global change in histone acetylation proba-
bly stems from the hierarchical nature of epigenetic transcrip-
tional control where DNA and histone methylation can provide a
dominant-repressive effect over histone acetylation. Consistent
with this, treatment of colon cancer cells with HDI or 5Aza alone
induced a different set of genes while combination therapy syn-
ergistically activated a subset of methylated genes, including a
number of putative tumor suppressors
(Yamashita et al., 2002) (Figure 1C).
Although altered gene regulation cer-
tainly occurs in tumors treated with HDIs,
other than CDKN1A, it is uncertain how
essential these genes are for the repro-
gramming of the cancer cell to differenti-
ate or cease growth.
The alternative mechanism-HDIs
induce apoptosis
HDIs can induce apoptosis of the cancer
cell, and their ability to activate proapo-
ptotic genes such as Fas and Bak sug-
gests that transcriptional regulation by
HDIs may play some role in the process
(Johnstone et al., 2002) (Figure 1B). However, in several sys-
tems, it appears that transit of cells through the G1/S boundary
and the accumulation of cells with a 4n DNA content are precur-
sors to cell death. As with many anticancer drugs, the intrinsic
apoptotic pathway involving activation of proapoptotic BH3-only
Bcl-2 proteins and mitochondrial membrane disruption is cen-
tral to HDI-mediated cell death (Figure 2). For example, SAHA-
induced apoptosis is associated with activation of the BH3-only
proapoptotic protein Bid, generation of reactive oxygen species,
and release of cytochrome c. Apoptosis induced by SAHA and
other HDIs is only partially blocked by a polycapsase inhibitor,
but almost completely blocked by overexpression of Bcl2 (Ruefli
et al., 2001; Henderson et al., 2003), emphasizing the impor-
tance of the intrinsic pathway but suggesting that noncaspase-
mediated events downstream of the mitochondria are at work.
SAHA-mediated Bid cleavage and apoptosis was blocked by a
calpain inhibitor (Mitsiades et al., 2003) and was cycloheximide
dependent (Ruefli et al., 2001), but whether SAHA directly mod-
ulates gene expression to activate the calpain/mitochondrial
apoptosis pathway is unknown.
The importance of p53 in HDI-mediated cell death is uncer-
tain. p53 is deacetylated and destabilized by class I and III
HDACs. Hence HDIs could augment p53 function to activate
genes encoding BH3-only proteins (i.e., PUMA, Noxa) and
thereby initiate the intrinsic apoptotic pathway. While most stud-
ies have indicated that HDI-mediated apoptosis can occur in the
absence of wild-type p53,a recent study using dominant-nega-
tive p53 suggested that HDI-mediated apoptosis required p53
(Henderson et al., 2003). A number of other apoptotic mecha-
nisms were described for HDIs including stimulation of JNK
activity and induction of Fas, Fas ligand and sensitization of
cells to the extrinsic pathway (Aron et al., 2003). These reports
are difficult to interpret, due to the fact that each study typically
utilizes different cell lines and different HDIs. A more systematic
study of several HDIs in the same cell line is needed, preferably
in cells with known mutations in genes critical for the regulation
of cell cycle arrest or apoptosis. The HCT116 cell line and sub-
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Figure 2. Mitotic model of anticancer effects of
HDIs
Hyperacetylation of the centromere induces
heterochromatin protein release, centrosome
dysfunction, and aberrant mitosis. Cells can
arrest in G2 or enter G1 and attempt to repli-
cate damaged DNA, which activates an apo-
ptotic cascade.
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clones in which p53, p21, and Bax have been deleted would be
a good starting point. Such experiments might also determine
which effects of structurally diverse HDIs are shared and attrib-
utable to inhibition of HDACs and which may be more specific to
the ability of the agents to affect other pathways.
HDI action may be unrelated to direct effects on gene
expression
While it is clear that HDIs can directly modulate gene expres-
sion through histone hyperacetylation, this may not be the
critical determinant of their antineoplastic actions. Histone-
mediated changes in gene expression per se may not be
responsible for apoptosis induced by HDIs, yet histones may
still be their primary targets. Histone acetylation in heterochro-
matin is tightly regulated during S phase, and disruption of this
process triggers cell cycle arrest within G2/M. The HDI-associ-
ated G2 checkpoint may be related to HDI-mediated
hyperacetylation of the centromere, allowing release of hete-
rochromatin proteins resulting in abnormal chromosomal segre-
gation and nuclear fragmentation (Taddei et al., 2001). In cancer
cells, the HDI-associated G2 checkpoint can be lost, leading to
aberrant mitoses and apoptosis (Qiu et al., 2000). Hence, it is
formally possible that dysregulated histone acetylation during S
phase and/or mitosis, rather than modulation of gene expres-
sion, may be the major event necessary for induction of HDI-
mediated cell death (Figure 2).
Why are cancer cells sensitive to HDIs?
The basis for the selective toxicity of cancer cells to HDIs is
unclear. If altered gene expression were the primary mecha-
nism for HDI-induced apoptosis, then one would expect both
normal cells and tumor cells to be equally sensitive. In fact,
given that the disruption of apoptotic pathways is an essential
event in tumorigenesis (Johnstone et al., 2002), it might be
expected that normal cells would be more sensitive than tumor
cells to HDI-induced death. If however HDI-induced apoptosis is
related to aberrant mitosis, then the fact that cancer cells uni-
versally lose cell cycle checkpoints can make these cells inher-
ently more sensitive to the agents. In support of this, leukemia
cell lines treated with HDI initially accumulate with a 4n DNA
content and then undergo apoptosis. However, if these cells are
manipulated to undergo arrest in G1 through overexpression of
p16INK4a, Bid is no longer activated and the cells remain viable,
although global histone hyperacetylation still occurs (R.W.J.,
unpublished data). Hence the loss of the G1 checkpoint, by loss
of p16INK4a or another mode of subversion of RB function, a vir-
tually universal occurrence in tumors, might explain the
increased sensitivity of cancer cells to HDIs.
A further unsolved question is what factors determine
whether a cancer cell undergoes cell cycle arrest, differentia-
tion, or death in response to HDIs. Drug levels are one factor as
most HDIs exhibit toxicity at higher doses and induce G1 arrest
at lower doses. Whether this is exclusively due to the effects of
HDI on chromatin remodeling and gene transcription is
unknown. Tissue type is another factor. At the same dose of
drug, one type of cell may undergo G1 arrest and differentiation
while another promptly undergoes apoptosis. Why this occurs is
completely obscure but might be related to the intracellular
metabolism of the drug or the specific subset of genetic defects
affecting regulation of the cell cycle or apoptosis in a particular
cancer cell. In support of the latter idea, the preexisting apoptot-
ic set point of the cell can alter the balance between HDI-
induced growth arrest and cell death. For example, cells
engineered to overexpress Bcl2 are resistant to HDI-mediated
apoptosis but the effects on the cell cycle are unaltered
(Johnstone, 2002). Furthermore, as noted, the decision of a cell
to arrest in G1 or progress through the cell cycle and experi-
ence the effects of HDIs on mitosis can determine cell fate. In
support of this idea, there is an inverse correlation between
p21WAF1/CIP1 induction and cell cycle arrest and apoptosis
(Burgess et al., 2001). If cells treated with HDI either cannot
induce p21WAF1/CIP1due to overriding epigenetic changes at the
CDKN1 locus or have functional defects in the G1 checkpoint,
then the cells may be destined to undergo apoptosis. We pro-
pose that the possible interplay between direct effects of HDI on
transcription and the indirect effects triggered by aberrant mito-
sis determine the ultimate biological outcome.
HDIs in clinical trial
HDIs as single agents have entered clinical trials (Kelly et al.,
2002). Phenyl butyrate was administered orally to treat solid
tumors and by continuous infusion in the myelodysplastic syn-
drome (MDS). A few patients in each trial had evidence of stable
disease or mild improvement. In these studies, it was difficult to
maintain drug levels and pulse dosing might be considered as
an alternative. A trial of depsipeptide achieved therapeutic lev-
els and one patient with cutaneous T cell lymphoma achieved a
complete response. Clinical trials of MS-275 (National Cancer
Institute), SAHA (Memorial Sloan Kettering Cancer Center),
Valproic acid (Mount Sinai School of Medicine), and others are
underway. In these studies, it will be critical to correlate clinical
response, accumulation of acetylated chromatin, changes in
gene regulation, and apoptosis. This is especially important
given the multiple ways by which HDIs may inhibit cancer cell
growth and survival (Table 1).
The transcriptional regulation model of HDI activity predicts
that combining HDIs with other agents will augment transcrip-
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Table 1. How histone deacetylase inhibitors may function in cancer therapy
Inhibition of cell proliferation
Augmentation of nuclear receptor response driving terminal cell 
differentiation
Reversal of repression by fusion transcription factors or overexpressed
repressors
Induction of p21, G1 arrest, and cellular differentiation
Reactivation of silenced tumor suppressor genes in combination with
DNA methyl transferase inhibitors
Suppression of telomerase gene expression
Induction of apoptosis
Activation of calpain/mitochondria-dependent apoptosis
Activation and or sensitization of death-receptor mediated killing
Mitotic dysfunction, aberrant chromosomal segregation, and DNA 
damage
Induction of topoisomerase II may alter sensitivity to DNA-damaging 
agents
Other mechanisms
Alteration of angiogenic signaling
Alteration of microtubule function
Induction of MHC antigens on the cell surface to augment immune 
responses
Suppression of IL-2-mediated gene expression
CANCER CELL : JULY 2003 17
tion of target genes and lead to differentiation. ATRA and HDIs
augment differentiation of APL and other types of myeloid
leukemia in vitro. In addition, HDIs plus G-CSF or 5 Aza induce
differentiation of leukemia cells harboring the AML1-ETO fusion
protein. Inhibition of DNA methylation with 5Aza reactivates epi-
genetically silenced genes and azacytidine induces improve-
ment in hematopoiesis in MDS. In one study, this was
associated with upregulation of p16INK4a (Daskalakis et al.,
2002). Successor trials are planned to treat MDS with the com-
bination of HDIs and 5Aza. On one hand, this therapy might
lead to further upregulation of silenced genes, growth arrest,
and differentiation of the malignant cells. However, it is equally
likely that DNA damage induced by 5 Aza, along with changes
in the apoptotic threshold induced by HDIs, could lead to selec-
tive apoptosis of the malignant cells and regrowth of normal
clones.Translational experiments that must be included in these
trials to prove that differentiated hematopoietic cells derive from
a malignant precursor should include fluorescence in situ
hybridization for marker chromosome detection, histone acety-
lation studies, monitoring of differential gene expression, and
apoptosis.
Should the counter theory that HDIs reset the apoptotic set
point be correct, combination therapy may still be required to
elicit the full effect of these agents. Such therapy might include
withdrawal of survival signals through RTK blockade, induction
of DNA damage by chemotherapy or radiation therapy, or induc-
tion of TNF receptor pathways.
Perspective
The study of HDIs in cancer, initially motivated by the study of
aberrant transcriptional repression, is rapidly evolving. It is now
apparent that the transcriptional effects of HDIs may be but one
facet of their action. In specific forms of cancer such as the
myeloid leukemias, HDIs may indeed be working as predicted to
block histone deacetylases and potentiate acetylation at specif-
ic genes. However, the focus on histone acetylation neglects the
many other facets of epigenetic regulation of gene expression.
True targeting of transcription in leukemia and other tumors
might require a combination of agents to modify chromatin,
including DNA methyl transferase inhibitors, histone methylase
inhibitors, HDIs, and specific stimulators of transcription factor
activity.
In the more common forms of cancer, HDIs are also promis-
ing therapeutic agents, but here their mechanism of action may
be quite different. HDIs have pleiotropic effects on cells, with
outputs of differentiation, growth arrest, and cell death all possi-
ble. It is not clear if transcription is the primary HDI target in
these cells, or if other effects, perhaps triggered by aberrant
mitosis, play a fundamental role. In patients, these effects may
be dependent on the particular genetic lesions of the tumor, the
dose and length of exposure of the tumor to drug, and the pos-
sibility that HDIs could affect secondary signaling pathways. A
combination of basic, clinical, and translational studies will ulti-
mately determine the clinical utility of these agents and their
mechanism of action.
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